Publication:
Metatypic carcinoma of the pancreas: delineation of a clinicopathologically distinct entity, characterized by centrally necrotic demarcated high-grade carcinoma with divergent patterns, basal immunophenotype, and altered molecular profile

Placeholder

Departments

School / College / Institute

Organizational Unit
Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Balcı, S.
Bakkaloğlu, I.G.
Altınmakas, E.
Pehlivanoğlu, B.
Bozkurtlar, E.
Luchini, C.
Mafficini, A.
Bevere, M.
Scarpa, A.
Cheng, J.D.

Editor & Affiliation

Compiler & Affiliation

Translator

Other Contributor

Date

Language

eng

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

A distinct type of pancreatic carcinoma (n=31; 6% of adenocarcinomas) is described, distinguished from conventional pancreatic ductal adenocarcinoma (PDAC) by: (1) solid/undifferentiated (sheet-like, stroma-poor) carcinomas lacking features of other entities (no osteoclasts, microsatellite stable, INI-1 retained, nonkeratinizing squamous <30%), often admixed with ordinary PDAC; (2) radiology/gross showing central necrosis/demarcation mimicking nonductal neoplasms, not scirrhous like PDAC; (3) marked intratumoral heterogeneity with divergent patterns, including basal/squamoid (81%), solid sheets punctuated with megavacuoles (77%), clear cell (68%), mucoepidermoid-like (36%), sarcomatoid (36%), and occasional choriocarcinomatous or angiosarcomatous patterns, and some with carcinomatous vasculitis; (4) cellular anaplasia with pleomorphic giant cells (55%), multinucleated nonosteoclastic (32%), and rhabdoid-like (32%); (5) immunohistochemically (n=16) consistently showing a basal phenotype with common GATA6 loss/depletion and/or CK5/6, p40, or p63 expression; (6) molecular-genetic profile (n=13) showing altered frequencies: ARID1A (31% vs. 4%) and CDKN2A/p16 (92% vs. 30%) alterations, universal KRAS mutations with enrichment in KRAS G12D, frequent TP53, and lower SMAD4 loss (8% vs. 55%). Limited follow-up suggests comparable or more favorable outcomes. In conclusion, this is a distinct type of carcinoma in the pancreas that is prone to being misdiagnosed as nonductal/non-PDAC cancers. It is the first pancreatic carcinoma type in which a basal molecular phenotype can be indicated clinically by both imaging and histopathology, with major potential management implications (as it is also enriched in actionable targets like ARID1A). Recognition of this category is critical for cancer research, as it offers an invaluable group to study plasticity, stroma versatility, necrosis mechanisms, and the basal type in pancreatic cancer.

Source

Publisher

Wolters Kluwer Health

Subject

Pathology, Surgery

Citation

Has Part

Source

The American Journal of Surgical Pathology

Book Series Title

Edition

DOI

10.1097/PAS.0000000000002513

item.page.datauri

Link

Rights

N/A

Copyrights Note

Creative Commons license

Except where otherwised noted, this item's license is described as N/A

Endorsement

Review

Supplemented By

Referenced By

Related Goal

0

Views

0

Downloads

View PlumX Details